Triple-Drug attack aims to shrink cervical cancer tumors
NCT ID NCT07627620
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a combination of three drugs—camrelizumab, famitinib, and standard chemotherapy—in 54 women with recurrent or metastatic cervical cancer that cannot be treated with surgery or radiation. The goal is to see if the combo shrinks tumors and controls the disease. Participants must not have had prior systemic therapy for advanced disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab, famitinib malate, and chemotherapy (paclitaxel + cisplatin or carboplatin)
- What this could lead to
- If it works, this could offer a new treatment option for people with cervical cancer that has come back or spread.
- What could go wrong
- This is an early Phase 2 trial with only 54 people, so results may not apply to everyone. The combination may cause side effects and might not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment